Celgene Rises as European Commission OKs Merger With Bristol-Myers By Investing.com

Investing.com – Celgene (NASDAQ:) was higher in midday trade on Monday after the European Union Commission gave its blessing for the biopharmaceutical company to merge with Bristol-Myers Squibb (NYSE:).

The approval from the commission is just one of a few regulatory hurdles the company faces before the acquisition is completed.

“Clearance from the European Commission is an important milestone toward completing our combination with Celgene and moves us one step closer to creating a leading biopharma company that is well positioned to develop and deliver innovative, meaningful medicines to patients,” said Giovanni Caforio, chairman and CEO of Bristol-Myers Squibb.

Bristol-Myers intends to close the deal by the beginning of 2020 at the latest. The acquisition was announced in January but has yet to be approved by the U.S. Federal Trade Commission.

Shares of Celgene (NASDAQ:) rose 0.3%, while Bristol-Myers gained 0.2%.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.